Information regarding the exact API (active pharmaceutical ingredient) price for Roflumilast is not publicly disclosed by manufacturers. Pharmaceutical pricing is complex and influenced by various factors, including manufacturing costs, research and development expenses, market demand, and agreements with distributors and pharmacies.
Who Manufactures Roflumilast API?
Several pharmaceutical companies are involved in the production of Roflumilast API. These may include both the originator company and generic manufacturers, especially as patents expire. Companies such as Aptalis Pharma (now part of AbbVie) have been associated with Roflumilast products. Generic API manufacturers worldwide also contribute to the supply chain.
When Did Roflumilast Patents Expire?
The patent landscape for Roflumilast is dynamic. The originator brand, Daliresp (or Daxas in some regions), was developed by Aptalis Pharma. Patents protecting the drug and its uses have been subject to expiration, which allows for the introduction of generic versions. Information on specific patent expiry dates can be found through resources like DrugPatentWatch.com [1].
What is the Price of Roflumilast Medication?
The retail price of Roflumilast medication, such as Daliresp or its generic equivalents, can vary significantly. Factors influencing this price include insurance coverage, pharmacy pricing, dosage, and whether a generic version is available. Patients often rely on prescription assistance programs or insurance plans to manage the cost of this medication.
Are There Generic Versions of Roflumilast Available?
Yes, generic versions of Roflumilast are available, particularly in markets where the primary patents have expired. The availability of generics typically leads to a reduction in the overall cost of treatment for patients.
How Does Roflumilast Work?
Roflumilast is a selective phosphodiesterase-4 (PDE4) inhibitor. By inhibiting PDE4, it increases intracellular cyclic adenosine monophosphate (cAMP) levels, which in turn reduces the inflammatory response in the lungs. This mechanism helps to alleviate symptoms associated with chronic obstructive pulmonary disease (COPD) [2].
What is Roflumilast Used For?
Roflumilast is primarily prescribed to reduce the risk of exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. It is an oral medication taken once daily [2].
What Are the Side Effects of Roflumilast?
Common side effects associated with Roflumilast can include diarrhea, weight loss, nausea, abdominal pain, and decreased appetite. More serious side effects, though less common, may also occur [2].
How Does Roflumilast Compare to Other COPD Treatments?
Roflumilast is a targeted anti-inflammatory therapy, distinct from bronchodilators (like LABAs and LAMAs) or inhaled corticosteroids, which are other common classes of COPD medications. It is often used as an add-on therapy for patients who remain symptomatic despite optimal treatment with these other agents [2].
What Clinical Data Supports Roflumilast Use?
Clinical trials have demonstrated Roflumilast's efficacy in reducing moderate to severe COPD exacerbations. These studies have evaluated its impact on exacerbation rates, lung function, and patient-reported outcomes in specific COPD populations [2].
Sources:
[1] DrugPatentWatch.com
[2] U.S. Food and Drug Administration. (n.d.). Daliresp Prescribing Information.